U.S. Markets open in 2 hrs 11 mins
  • S&P Futures

    4,261.00
    +5.00 (+0.12%)
     
  • Dow Futures

    34,187.00
    +105.00 (+0.31%)
     
  • Nasdaq Futures

    14,377.50
    +23.25 (+0.16%)
     
  • Russell 2000 Futures

    2,334.50
    +3.30 (+0.14%)
     
  • Crude Oil

    73.15
    -0.15 (-0.20%)
     
  • Gold

    1,782.50
    +5.80 (+0.33%)
     
  • Silver

    26.22
    +0.17 (+0.65%)
     
  • EUR/USD

    1.1947
    +0.0013 (+0.1075%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    16.00
    -0.32 (-1.96%)
     
  • GBP/USD

    1.3904
    -0.0017 (-0.1237%)
     
  • USD/JPY

    110.7600
    -0.0750 (-0.0677%)
     
  • BTC-USD

    33,643.41
    +242.49 (+0.73%)
     
  • CMC Crypto 200

    801.91
    +15.29 (+1.94%)
     
  • FTSE 100

    7,119.69
    +9.72 (+0.14%)
     
  • Nikkei 225

    29,066.18
    +190.95 (+0.66%)
     

MedTech Round Up: Update On Products By Conformis, Medtronic, Orthofix, Neovasc

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The FDA has given 510(k) clearance for Conformis Inc's (NASDAQ: CFMS) Identity Imprint Knee Replacement System, available in both cruciate-retaining (CR) and posterior stabilized (PS) versions.

  • Identity Imprint utilizes a proprietary 3-dimensional "best-fit" algorithm to select the implant that most closely meets the geometric and anatomic requirements of the patient based on the patient's computed tomography scans.

  • Price Action: CFMS shares are trading 6.95% higher at $0.90 during the market trading session on the last check Monday.

Medtronic plc (NYSE: MDT) has announced the U.S. commercial launch of the SonarMed airway monitoring system, a pediatric monitor to check endotracheal tube (ETT) obstruction and verify position in real-time.

  • SonarMed, which Medtronic acquired in December 2020, specializes in developing solutions that increase patient safety while significantly decreasing healthcare costs.

  • Price Action: MDT shares are up 0.43% at $127.24 during the market trading session on the last check Monday.

The FDA has given 510(k) clearance to Orthofix Medical Inc's (NASDAQ: OFIX) OrthoNext digital platform, a software tool for deformity analysis and preoperative planning for pediatric orthopedic procedures.

  • Developed specifically for use with the JuniOrtho Plating System, the OrthoNext digital platform software enables the surgeon to plan the osteotomy position accurately to visualize the implant concerning the anatomy.

  • The company has initiated its U.S. and European full market launch of the JuniOrtho Plating System.

  • Price Action: OFIX shares are down 4.05% at $42.37 during the market trading session on the last check Monday.

Neovasc Inc (NASDAQ: NVCN) has enrolled the first patient in the COSIMA trial investigating the company's Reducer for the treatment of Microvascular Angina.

  • The study will enroll up to 144 patients across multiple centers in Germany. The primary endpoint of the study is the change in CCS angina class, a measure of chest pain severity and limitation, by two or more classes.

  • The Reducer is CE-marked in the European Union to treat refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle.

  • Price Action: NVCN shares are down 3.2% at $0.83 during the market trading session on the last check Monday.

See Benzinga's FDA Calendar

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.